People with HIV (PWH) are facing multiple challenges in the battle against weight gain, including the growing, worldwide obesity epidemic and its drivers, normal aging and HIV- and antiretroviral therapy (ART)-associated contributors. The worldwide obesity epidemic is beyond the scope of this talk but must be considered when assessing individual patient risk and treatment options. HIV itself appears to promote fat gain and lean mass loss greater than expected for age, creating additional challenges. Finally, while ART initiation is universally associated with generalized weight gain, some PWH experience excessive (>10%) weight gain following initiation of or switch to newer agents, particularly bictegravir, dolutegravir and tenofovir alafenamide. This presentation will review the available evidence on weight gain in PWH, discuss potential treatment options and highlight research questions important to optimizing weight for PWH.
CROI Conference
